We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Invion Limited is a drug manufacturers-specialty & generic business based in Australia. Invion shares (IVX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Invion has a trailing 12-month revenue of around $2.3 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.008 - $0.034 |
|---|---|
| 50-day moving average | $0.0184 |
| 200-day moving average | $0.0136 |
| Target price | $0.11 |
| PE ratio | 1.6117 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.0003 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.017
| 1 week (2021-11-25) | -5.56% |
|---|---|
| 1 month (2021-11-05) | -26.09% |
| 3 months (2021-09-03) | 30.77% |
| 6 months (2021-06-04) | 0.017 |
| 1 year (2020-12-04) | 41.67% |
|---|---|
| 2 years (2019-12-05) | 21.43% |
| 3 years (2018-12-05) | -5.56% |
| 5 years (2016-12-05) | 608.33% |
Valuing Invion stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Invion 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Invion 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Invion shares trade at around 2x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $2.3 million |
|---|---|
| Gross profit TTM | $810,505 |
| Return on assets TTM | -17.24% |
| Return on equity TTM | -2900.75% |
| Profit margin | -63.65% |
| Book value | 0.001 |
| Market capitalisation | $109 million |
TTM: trailing 12 months
We're not expecting Invion to pay a dividend over the next 12 months.
Over the last 12 months, Invion 's shares have ranged in value from as little as $0.008 up to $0.034. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Invion 's is 1.8915. This would suggest that Invion 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
Steps to owning and managing Coles Group shares from .
Polestar and Phoenix will likely be the next IPOs in a very hot sector led by recently launched Rivian and Lucid and by China’s Nio. They won’t be the last.
A cryptic tweet from the Tesla and SpaceX founder has reignited speculation about an initial public offering, here’s what it might look like.
Wellington Phoenix and Western Sydney will battle for early season momentum in a big A-League clash.
Worry about the new coronavirus variant Omicron is lifting some vaccine stocks.
We've rounded up where you can shop every product the TikTok star uses in her Vogue Beauty Secrets tutorial, plus a few affordable dupes.
The 10 biggest movers on the ASX for Friday 3 December 2021.
Shares in biotech giant CSL are down 4% in the past week alone.
Basketball fans have plenty to look forward to in the 2021/22 NBL season. Here's how to tune in and our prediction for the year.
